Influence of C-peptide on early glomerular changes in diabetic mice

Diabetes/Metabolism Research and Reviews

Volumn 22, Issue 4, 2006, Pages 313-322

  Maezawa, Yoshiro ^a   Yokote, Koutaro ^a   Sonezaki, Kiriko ^a   Fujimoto, Masaki ^a   Kobayashi, Kazuki ^a   Kawamura, Harukiyo ^a   Tokuyama, Takahiko ^a   Takemoto, Minoru ^b   Ueda, Shiro ^c   Kuwaki, Tomoyuki ^a   Mori, Seijiro ^a   Wahren, John ^b   Saito, Yasushi ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KAROLINSKA INSTITUTE   (Sweden)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

C peptide; Diabetic nephropathy; ERK; Streptozotocin; TGF ; Type IV collagen

Indexed keywords

ALBUMIN; C PEPTIDE; COLLAGEN TYPE 4; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PERTUSSIS TOXIN; STREPTOZOCIN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GLOMERULOPATHY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PODOCYTE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; TRANSCRIPTION REGULATION; UPREGULATION; URINARY EXCRETION;

ALBUMINURIA; ANIMALS; BLOOD PRESSURE; C-PEPTIDE; COLLAGEN TYPE IV; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DNA PRIMERS; GENE EXPRESSION REGULATION; KIDNEY GLOMERULUS; MICE; PERTUSSIS TOXIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMERASE CHAIN REACTION; PROTEIN KINASES; RATS; TRANSFORMING GROWTH FACTOR BETA;

EID: 33746049207     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.612     Document Type: Article

References (50)

1. Parving H-H, Osterby R, Ritz E. Diabetic Nephropathy. In The Kidney. (6th edn), Brenner BM, Levine S (eds). WB Saunders: Philadelphia, PA, 2000; 1731-1773.
2. Mogensen CE, Cooper ME. Diabetic renal disease: from recent studies to improved clinical practice. Diabet Med 2004; 21: 4-17.
3. Johansson BL, Sjoberg S, Wahren J. The influence of human C-peptide on renal function and glucose utilization in type 1 (insulin-dependent) diabetic patients. Diabetologia 1992; 35: 121-128.
4. Johansson BL, Kernell A, Sjoberg S, Wahren J. Influence of combined C-peptide and insulin administration on renal function and metabolic control in diabetes type 1. J Clin Endocrinol Metab 1993; 77: 976-981.
5. Johansson BL, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus. Diabet Med 2000; 17: 181-189.
6. Sjoquist M, Huang W, Johansson BL. Effects of C-peptide on renal function at the early stage of experimental diabetes. Kidney Int 1998; 54: 758-764.
7. Samnegard B, Jacobson SH, Jaremko G, Johansson BL, Sjoquist M. Effects of C-peptide on glomerular and renal size and renal function in diabetic rats. Kidney Int 2001; 60: 1258-1265.
8. Huang DY, Richter K, Breidenibach A, Vallon V. Human C-peptide acutely lowers glomerular hyperfiltration and proteinuria in diabetic rats: a dose-response study. Naunyn Schmiedebergs Arch Pharmacol 2002; 365: 67-73.
9. Samnegard B, Jacobson SH, Jaremko G, et al. C-peptide prevents glomerular hypertrophy and mesangial matrix expansion in diabetic rats. Nephrol Dial Transplant 2005; 20: 532-538.
10. Ohtomo Y, Aperia A, Sahlgren B, Johansson BL, Wahren J. C-peptide stimulates rat renal tubular Na+, K(+)-ATPase activity in synergism with neuropeptide Y. Diabetologia 1996; 39:199-205.
11. Rigler R, Pramanik A, Jonasson P, et al. Specific binding of proinsulin C-peptide to human cell membranes. Proc Natl Acad Sci U S A 1999; 96: 13318-13323.
12. +-ATPase activity via PKC alpha in rat medullary thick ascending limb. Diabetologia 2003; 46: 124-131.
13. Ido Y, Vindigni A, Chang K, et al. Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science 1997; 277: 563-566.
14. Al-Rasheed NM, Meakin F, Royal EL, et al. Potent activation of multiple signalling pathways by C-peptide in opossum kidney proximal tubular cells. Diabetologia 2004; 47: 987-997.
15. Zhong Z, Kotova O, Davidescu. A, et al. C-peptide stimulates Na+, K+-ATPase via activation of ERKI/2 MAP kinases in human renal tubular cells. Cell Mol Life Sci 2004; 61: 2782-2790.
16. Wallerath T, Kunt T, Forst T, et al. Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide. Nitric Oxide 2003; 9: 95-102.
17. Kitamura T, Kimura K, Makondo K, et al. Proinsulin C-peptide increases nitric oxide production by enhancing mitogen-activated protein-kinase-dependent transcription of endothelial nitric oxide synthase in aortic endothelial cells of Wistar rats. Diabetologia 2003; 46: 1698-1705.
18. Wahren J, Ekberg K, Shafqat J, Johansson J, Johansson BL, Jömvall H. Biological effects of C-peptide and Proinsulin. In International Textbook of Diabetes Mellitus (3rd edn), DeFronzo RA, Ferrannini E, Keen H, Zimmet P (eds). John Wiley & sons: Chichester, 2004; 165-181.
19. Wahren J. C-peptide: new findings and therapeutic implications in diabetes. Clin Physiol Funct Imaging 2004; 24: 180-189.
20. Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 2003; 14: 1358-1373.
21. Takemoto M, Asker N, Gerhardt H, et al. A new method for large scale isolation of kidney glomeruli from mice. Am J Pathol 2002; 161:799-805.
22. Mundel P, Reiser J, Zuniga Mejia Borja A, et al. Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 1997; 236: 248-258.
23. Yokote K, Mori S, Hansen K, et al. Direct interaction between Shc and the platelet-derived growth factor β-receptor. J Biol Chem 1994; 269: 15337-15343.
24. Fujimoto M, Maezawa Y, Yokote K, et al. Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochem Biophys Res Commun 2003; 13: 1002-1007.
25. Mizuno S, Nakamura T. Suppressions of chronic glomerular injuries and TGF-b1 production by HGF in attenuation of murine diabetic nephropathy. Am J Physiol Renal Physiol 2004; 286: F134-F143.
26. Heidet L, Cai Y, Guicharnaud L, Antignac C, Gubler MC. Glomerular expression of type IV collagen chains in normal and X-linked Alport syndrome kidneys. Am J Pathol 2000; 156: 1901-1910.
27. Marshal SM. The podocyte: a major player in the development of diabetic nephropathy? Horm Metab Res 2005; 37(Suppl 1): 9-16.
28. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54: 1626-1634.
29. Iglesias-de la Cruz MC, Ziyadeh FN, Isono M, et al. Effects of high glucose and TGF-betal on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int 2002; 62: 901-913.
30. Laiho M, Saksela O, Andreasen PA, Keski-Oja J. Enhanced production and extracellular deposition of the endothelial-type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-β. J Cell Biol 1986; 103: 2403-2410.
31. Keeton MR, Curriden SA, van Zonneveld AJ, Loskutoff DJ. Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor β. J Biol Chem 1991; 266: 23048-23052.
32. Kitamura T, Kimura K, Jung BD, et al. Proinsulin C-peptide rapidly stimulates mitogen-activated protein kinases in Swiss 3T3 fibroblasts: requirement of protein phosphoinositide 3-kinase and pertussis toxin-sensitive G-protein. Biochem J 2001; 355: 123-129.
33. Li ZG, Zhang W, Sima AA. C-peptide enhances insulin-mediated cell growth and protection against high glucose-induced apoptosis in SH-SY5Y cells. Diabetes Metab Res Rev 2003; 19: 375-385.
34. Kitamura T, Kimura K, Jung BD, et al. Proinsulin C-peptide activates cAMP response element-binding proteins through the p38 mitogen-activated protein kinase pathway in mouse lung capillary endothelial cells. Biochem J 2002; 366: 737-744.
35. Zhong Z, Davidescu A, Ehren I, et al. C-peptide stimulates ERK1/2 and JNK MAP kinases via activation of protein kinase C in human renal tubular cells. Diabetologia 2005; 48: 187-197.
36. Breyer MD, Bottinger E, Brosius FC 3rd, et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol 2005; 16: 27-45.
37. Makino H, Shikata K, Hayashi T, et al. Immunoreactivity of the JK-132 monoclonal antibody directed against basement membrane collagen in normal and diabetic glomeruli. Virchows Arch 1994; 424: 235-241.
38. Yagame M, Kim Y, Zhu D, et al. Differential distribution of type IV collagen chains in patients with diabetic nephropathy in non-insulin-dependent diabetes mellitus. Nephron 1995; 70: 42-48.
39. Iwano M, Kubo A, Nishino T. Quantification of glomerular TGF-beta 1 mRNA in patients with diabetes mellitus. Kidney Int 1996; 49:1120-1126.
40. Sharma K, Ziyadeh FN, Alzahabi B, et al. Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 1997; 46: 854-859.
41. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A 1993; 90: 1814-1818.
42. Reeves WB, Andreoli TE. Transforming growth factor beta contributes to progressive diabetic nephropathy. Proc Natl Acad Sci U S A 2000; 97: 7667-7669.
43. Ziyadeh FN, Sharma K, Ericksen M, Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest 1994; 93: 536-542.
44. Suzuki S, Ebihara I, Tomino Y, Koide H. Transcriptional activation of matrix genes by transforming growth factor beta 1 in mesangial cells. Exp Nephrol 1993; 1: 229-237.
45. Pera. EM, Ikeda A, Eivers E, De Robertis EM. Integration of IGF, FGF and anti-BMP signals via Smad1 phosphorylation in neural induction. Genes Dev 2003; 17: 3023-3028.
46. Kretzshmar M, Doody J, Massagué J. Opposing BMP and EGF signaling pathways converge on the TGF-β family mediator Smad1. Nature 1997; 389: 618-622.
47. Grimm OH, Gurdon JB. Nuclear exclusion of Smad2 is a mechanism leading to loss of competence. Nat Cell Biol 2002; 4: 519-522.
48. Massagué J. Integration of MAPK and Smad pathways: a link and a linker revisited. Genes Dev 2003; 17: 2993-2997.
49. Grunberger G, Qiang X, Li Z, et al. Molecular basis for the insulinomimetic effects of C-peptide. Diabetologia 2001; 44: 1247-1257.
50. Li ZG, Zhang W, Sima AA. C-peptide enhances insulin-mediated cell growth and protection against high glucose-induced apoptosis in SH-SY5Y cells. Diabetes Metab Res Rev 2003; 19: 345-347.